EXTRACELLULAR VESICLE-DIRECTED POLYPEPTIDE TAG
The present invention is based on the surprising finding that Wnt7a, and other Wnt family members, are trafficked to extracellular vesicles (EVs) via interactions with coatomer proteins. Extracellular vesicle signal peptides (ESPs), each comprising at least one key Coatomer binding motif (CBM), are described, and these mediate EV trafficking of Wnt family members. The ESPs may be used to target other proteins for display on EVs. Herein is described an EV comprising: COPI, and a recombinant EV-directed polypeptide comprising: a cargo polypeptide, and an ESP comprising a CBM, wherein the cargo polypeptide is tethered to an external surface of the EV via the coatomer binding motif. Also described are recombinant EV-directed polypeptides comprising an ESP and a cargo. Additionally described are recombinant skeletal muscle-targeted EVs comprising a payload polypeptide; and recombinant Wnts having mutated CBM or ESPs, which are less trafficked to EVs for production/recovery of free Wnts..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Europäisches Patentamt - (2022) vom: 10. Nov. Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
RUDNICKI MICHAEL A [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2022-11-10, Last update posted on www.tib.eu: 2023-11-09, Last updated: 2023-11-17 |
|---|
| Patentnummer: |
WO2022232924 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA016533593 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA016533593 | ||
| 003 | DE-627 | ||
| 005 | 20231117102356.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230607s2022 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA016533593 | ||
| 035 | |a (EPA)WO2022232924 | ||
| 035 | |a (EPA)83932003 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a RUDNICKI MICHAEL A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a EXTRACELLULAR VESICLE-DIRECTED POLYPEPTIDE TAG |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2022-11-10, Last update posted on www.tib.eu: 2023-11-09, Last updated: 2023-11-17 | ||
| 520 | |a The present invention is based on the surprising finding that Wnt7a, and other Wnt family members, are trafficked to extracellular vesicles (EVs) via interactions with coatomer proteins. Extracellular vesicle signal peptides (ESPs), each comprising at least one key Coatomer binding motif (CBM), are described, and these mediate EV trafficking of Wnt family members. The ESPs may be used to target other proteins for display on EVs. Herein is described an EV comprising: COPI, and a recombinant EV-directed polypeptide comprising: a cargo polypeptide, and an ESP comprising a CBM, wherein the cargo polypeptide is tethered to an external surface of the EV via the coatomer binding motif. Also described are recombinant EV-directed polypeptides comprising an ESP and a cargo. Additionally described are recombinant skeletal muscle-targeted EVs comprising a payload polypeptide; and recombinant Wnts having mutated CBM or ESPs, which are less trafficked to EVs for production/recovery of free Wnts. | ||
| 650 | 4 | |a bio | |
| 650 | 4 | |a C12P: Fermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a C12N: Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000) | |
| 650 | 4 | |a C07K: Peptides (peptides containing β-lactam rings c07d;cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, c07d;ergot alkaloids of the cyclic peptide type c07d0519020000; single cell proteins, enzymes c12n;genetic engineering processes for obtaining peptides c12n0015000000) | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a GURRIARAN-RODRIGUEZ UXIA |4 aut | |
| 700 | 0 | |a DATZKIW DAVID ALEXANDER |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2022) vom: 10. Nov. |
| 773 | 1 | 8 | |g year:2022 |g day:10 |g month:11 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/83932003/publication/WO2022232924A1?q=WO2022232924 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2022 |b 10 |c 11 |
| 951 | |a AR | ||
| 952 | |j 2022 |b 10 |c 11 | ||